|Dr. David Raymond Koos||Chairman, CEO, Pres, Sec. & Treasurer||N/A||N/A||1961|
Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It intends to develop small molecule NR2F6 that activates to immune cell for oncology and autoimmune diseases. The company was incorporated in 2012 and is based in La Mesa, California.
Regen BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.